William Blair Has Bullish Estimate for Amgen FY2028 Earnings

Amgen Inc. (NASDAQ:AMGN) – Investment analysts at William Blair boosted their FY2028 earnings per share (EPS) estimates for Amgen in a report released on Wednesday, February 5th. William Blair analyst M. Phipps now anticipates that the medical research company will post earnings per share of $20.89 for the year, up from their prior forecast of $20.80. William Blair currently has a “Outperform” rating on the stock. The consensus estimate for Amgen’s current full-year earnings is $19.56 per share.

Several other equities research analysts have also recently commented on AMGN. UBS Group dropped their target price on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a research report on Thursday, October 31st. Cantor Fitzgerald restated an “overweight” rating and issued a $405.00 price objective on shares of Amgen in a report on Tuesday, October 22nd. Citigroup decreased their target price on Amgen from $310.00 to $295.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. StockNews.com lowered Amgen from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, December 18th. Finally, Wolfe Research began coverage on Amgen in a report on Friday, November 15th. They issued a “peer perform” rating for the company. Two analysts have rated the stock with a sell rating, twelve have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $314.83.

Amgen Trading Up 6.5 %

Shares of AMGN opened at $307.81 on Thursday. Amgen has a twelve month low of $253.30 and a twelve month high of $346.85. The stock has a market capitalization of $165.46 billion, a P/E ratio of 39.41, a PEG ratio of 2.87 and a beta of 0.56. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The firm has a fifty day simple moving average of $271.69 and a two-hundred day simple moving average of $303.55.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 4th. The medical research company reported $5.31 EPS for the quarter, beating analysts’ consensus estimates of $5.04 by $0.27. Amgen had a return on equity of 168.35% and a net margin of 13.00%.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date is Friday, February 14th. This represents a $9.52 dividend on an annualized basis and a yield of 3.09%. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Institutional Investors Weigh In On Amgen

A number of institutional investors and hedge funds have recently bought and sold shares of the company. AMF Tjanstepension AB boosted its stake in Amgen by 16.9% in the third quarter. AMF Tjanstepension AB now owns 120,389 shares of the medical research company’s stock valued at $38,825,000 after acquiring an additional 17,387 shares in the last quarter. Czech National Bank raised its position in Amgen by 7.1% during the third quarter. Czech National Bank now owns 109,459 shares of the medical research company’s stock valued at $35,269,000 after acquiring an additional 7,237 shares in the last quarter. City Center Advisors LLC purchased a new position in shares of Amgen during the 3rd quarter valued at approximately $220,000. Atomi Financial Group Inc. boosted its stake in shares of Amgen by 4.2% during the 3rd quarter. Atomi Financial Group Inc. now owns 5,388 shares of the medical research company’s stock worth $1,736,000 after acquiring an additional 217 shares in the last quarter. Finally, City Holding Co. boosted its stake in shares of Amgen by 0.6% in the third quarter. City Holding Co. now owns 10,719 shares of the medical research company’s stock worth $3,454,000 after acquiring an additional 67 shares during the last quarter. 76.50% of the stock is owned by institutional investors.

Amgen Company Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.